Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) from a sell rating to a hold rating in a report issued on Monday morning.

A number of other equities analysts also recently commented on the stock. Maxim Group lifted their target price on shares of Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a buy rating in a research note on Tuesday, March 19th. Cantor Fitzgerald reaffirmed an overweight rating and set a $21.00 price target on shares of Actinium Pharmaceuticals in a research report on Monday, April 1st. Finally, HC Wainwright reiterated a buy rating and issued a $50.00 price objective on shares of Actinium Pharmaceuticals in a report on Monday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of Moderate Buy and an average price target of $25.72.

Actinium Pharmaceuticals Trading Up 1.3 %

NYSEAMERICAN ATNM opened at $7.80 on Monday. The firm has a market cap of $232.28 million, a price-to-earnings ratio of -4.56 and a beta of 0.01. Actinium Pharmaceuticals has a fifty-two week low of $4.00 and a fifty-two week high of $9.86.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last posted its quarterly earnings results on Friday, March 29th. The biotechnology company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.21. The company had revenue of $0.08 million for the quarter. Equities analysts anticipate that Actinium Pharmaceuticals will post -1.87 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ATNM. Sanders Morris Harris LLC acquired a new position in shares of Actinium Pharmaceuticals in the first quarter worth $78,000. Creative Financial Designs Inc. ADV boosted its holdings in Actinium Pharmaceuticals by 19.1% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 3,175 shares during the period. Finally, Brandywine Global Investment Management LLC acquired a new position in Actinium Pharmaceuticals during the 3rd quarter worth $1,033,000. 27.50% of the stock is currently owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.